Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol

Contributed by: GlobeNewswire

Tags

nuclear medicine

More Like This

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

PR Newswire associated0

Scintimun® Commercialization Partnership with Curium Pharma

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

PR Newswire associated0

Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply

PR Newswire associated0

Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals

PR Newswire associated0

Global supply chain for Lu-177 based cancer treatments strengthened by Kinectrics' start of Yb-176 production, reducing reliance on Russia

PR Newswire associated0

Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform

PR Newswire associated0

Blue Earth Therapeutics Reports Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial